HC Wainwright Expects Lower Earnings for Bicara Therapeutics

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Bicara Therapeutics in a report released on Monday, April 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.40) for the quarter, down from their prior estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.73) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

Several other equities analysts have also recently weighed in on the company. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Trading Up 6.1 %

Shares of BCAX stock opened at $10.77 on Thursday. Bicara Therapeutics has a 1 year low of $8.91 and a 1 year high of $28.09. The stock has a 50 day simple moving average of $12.76 and a 200 day simple moving average of $16.82.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently modified their holdings of BCAX. California State Teachers Retirement System acquired a new stake in Bicara Therapeutics in the fourth quarter valued at about $25,000. Spire Wealth Management bought a new position in shares of Bicara Therapeutics in the fourth quarter worth about $31,000. BNP Paribas Financial Markets bought a new position in shares of Bicara Therapeutics in the fourth quarter worth about $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at approximately $33,000. Finally, Summit Investment Advisors Inc. bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at approximately $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.